The Hybrid Solution for Joint Pain that drawn Attention by WHO!

Joint pain and osteoarthritis are one of the most important patient complaints all over the world. The World Health Organization (WHO) estimates that by 2050, 130 million people worldwide will suffer from joint pain and osteoarthritis. Again, according to the World Health Organization, 40 million people will lose their functions due to osteoarthritis by 2050.

Scientists have made an important discovery against joint pain and calcification, which the whole world seeks for remedies and causes significant economic losses. Developed with hybrid technology, HYDRAVIC received full marks from health authorities. HYDRAVIC, which minimizes the wear on the cartilage and slows down the pressure created by the body on the cartilage, prevents patients from complaining of pain for up to 6-8 months.

Degeneration of the joints significantly complicates daily life. In an online survey of more than 24,000 people from 24 countries, 87% of respondents said they had experienced joint pain. Approximately 20% of the world’s population has joint pain and osteoarthritis complaints. 77% of people who experience joint pain state that their pain affects their daily life. Joint pain and osteoarthritis cause depression, anxiety, and social isolation.

The country with the highest prevalence of osteoarthritis in the world is the USA. In the United States, more than half of adults with osteoarthritis (18.7 million) are of working age (18-64 years). Therefore, osteoarthritis also leads to a significant loss of workforce. In a study conducted in the USA, annual labor loss due to osteoarthritis was calculated as 71.3 billion dollars in the 2008-2014 period.


Against joint pain and osteoarthritis, which the world is seeking a cure for, scientists have made an innovative development in intra-articular fluids. Turkish scientists have developed an intra-articular injection with the most compatible gel form with hybrid production technology. Launched under the HYDRAVIC brand, the product attracts great attention all over the world.

Developed with hybrid technology and minimizing the wear on cartilage, HYDRAVIC prevents patients from complaining of pain for up to 6-8 months. Turkish scientists who developed HYDRAVIC state that patient complaints will decrease significantly.


HYDRAVIC, one of the first intra-articular injections with hybrid production technology in Turkey, stands out with its patient satisfaction. Stating that HYDRAVIC minimizes the wear on the cartilage and slows down the pressure created by the body on the cartilage, Prof. Serdar Sezer said, “Patient satisfaction is very good. Hybrid technology is a system that is applied for the first time in Turkey as well as in the world. HYDRAVIC prevents patients from complaining of pain for up to 6-8 months.”


Prof Sezer pointed out the importance of the hybrid technology used in the production of HYDRAVIC, “This has been proven in in vitro and in vivo experiments. The clinical long-term responses are very good. In the studies we have done while developing these products, we have observed studies with a longer duration of action with our innovative approach that replicates proven results around the world. Afterwards, we are happy to introduce such a product to the market in the injection market, where we are one of the leading manufacturers in its field. We apply similar approaches in all our product models.” said.

Stating that they minimize the pain experienced by the patients during the injection, Sezer said, “What makes HYDRAVIC different from other products is its technology. It is a product that does not make the patient feel very low or no pain during the injection and relieves the patient’s pain in a short time. In this technology, in addition to the molecular interaction, post-injection pain and swelling etc. due to the production of the product in aseptic technical infrastructure. We minimize such complaints as much as possible.”


Stating that Europe’s largest pharmaceutical and medical device R&D Center in the field of biomaterials was established in Turkey, Sezer said, “Equipped infrastructures require very serious costs to produce such products. Many companies do not want to invest in such product groups, which have high infrastructure costs and are difficult to produce. With the new legislation, the costs increase significantly. We reach an annual capacity of 5.4 million units in 2023 in the HYDRAVIC production line, where we have achieved great success in the medical market.” 

Leave a Reply

Your email address will not be published.